Torres PML, Santiago AC

Language: Spanish
References: 9
Page: 291-295
PDF size: 50.69 Kb.

ABSTRACT

Nowadays, it is known that platelets are the main agents involved in the pathogenesis of acute coronary syndromes, and the fact that aspirin is a weak antiplatelet agent has led to an intensive research in antiplatelet drugs in the last years. The medical literature from the last decade containes many studies on the use of platelet IIb/IIIa receptor blockers in different clinical settings. Agents that block the IIb/IIIa platelet receptor have shown to be useful in improving prognosis of patients with acute coronary syndromes (ACS), especially in those studies of percutaneous coronary revascularization procedures. However, their potential risk of causing bleeding and high cost have prevented applied universal and routine application. There are some aspects, such as correct dosage, optimal duration of treatment, and direct comparison of the efficacy of different types of IIb/IIIa blockers, that not have not been resolved yet. On the other hand, oral IIb/IIIa antagonists have not exceeded the efficacy of aspirin. Finally, it is necessary to identify those patients that will obtain the most benefit from this treatment to avoid unnecessary risks and costs. Therefore, it is very important, for the nurse to have the necessary knowledge on the therapeutic effect and use of this antiplatelets therapy, to be able to identify in time any complication that night increase the risk and in danger the patient’s life.

REFERENCES

1. Ross R: The pathogenesis of atheroesclerosis. In: Braunwald E (ED): Heart Disease: a Texbok ot cardiovascular Medicine. 4th ed. Philadelphia: WB Saunders Co., 1992; 1106-24.

2. Cooccheri S, Palareti G, Fortunato G: Antithrombotic Drugs in peripheral obliterative arterial disease. Haemostasis 1994; 24: 118-27.

3. Dyke CM: Safety of glicoprotein IIbIIIa inhibitors: A heart surgeon’ perspective. Am Heart J 1999; 138(4 Pt 2): 307-16.

4. Juran NB: Minimizing Bleeding complications of percutaneous coronary intervention and glycoprotein IIbIIIa antiplatelet therapy. Am Heart J 1999; 138 (4pt 2): 297-306.

5. Harrintong RA: Overview of clinical trials of glicoprotein IIb/IIa inhibitors in acute coronary syndromes. Am Heart J 1999; 138(4 pt 2): 297-306.

6. CAPRIE Steering Committee: A randomized, blinded, trial of clopidrogel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.

7. F Ramier RN; Thomas RPT: Anticoagulantes “Como utilizarlos de forma segura y eficaz. Nursing 1995; 13(8):17-20.

8. Schafer AI: Antiplatalet therapy. Am J Med 1996; 101: 199-209.

9. Antiagregantes plaquetarios. PAM 1998; 22(218): 704-707.